Stocktoria
LifeStance Health Group, Inc. LFST
LifeStance Health Group, Inc. (LFST) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $1.4B at a 0.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-05 | Goldman Sachs | Neutral (init) |
| 2026-05-14 | JP Morgan | Neutral (main) |
| 2026-05-08 | BTIG | Buy (main) |
| 2026-03-06 | Barclays | Overweight (main) |
| 2026-02-26 | Canaccord Genuity | Buy (main) |
| 2026-02-26 | UBS | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.075 |
| Retained earnings / assets | -0.367 |
| EBIT / assets | 0.011 |
| Equity / liabilities | 2.227 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | 7/9 | 1.7 | 412.6 | +13.9% |
| PIII | P3 Health Partners Inc. | 2/9 | -10.32 | — | -2.8% |
| PNTG | Pennant Group, Inc. | 3/9 | 1.45 | 42.2 | +36.3% |
| INNV | InnovAge Holding Corp. | 6/9 | 0.08 | — | +11.8% |
| USPH | U S PHYSICAL THERAPY INC /NV | 6/9 | 2.26 | 25.5 | +16.3% |
| PRVA | Privia Health Group, Inc. | 5/9 | 2.87 | 140.6 | +22.3% |
| WGS | GeneDx Holdings Corp. | 6/9 | -5.22 | — | +40% |
About LifeStance Health Group, Inc.
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
FAQ
Is LFST financially healthy?
LifeStance Health Group, Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does LFST pay a dividend?
No, LifeStance Health Group, Inc. does not currently pay a dividend.
How profitable is LFST?
In FY2025, LifeStance Health Group, Inc. had a net margin of 0.7% and a return on equity of 0.6%.
What is LFST's P/E ratio?
LifeStance Health Group, Inc.'s trailing price-to-earnings (P/E) ratio is about 412.6×, based on its latest annual earnings.
What is the analyst price target for LFST?
The average Wall-Street price target for LifeStance Health Group, Inc. is $10.55, about 13.7% below the recent price, from 10 analysts.
Is LFST a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LifeStance Health Group, Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the grey zone, a P/E of about 412.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.